Shares of Arcutis Biotherapeutics Inc. (ARQT) surged 8.36% in after-hours trading on Tuesday following the release of the company's strong fourth quarter 2024 financial results. The biopharmaceutical company's performance was driven by better-than-expected revenue and earnings, fueled by rapidly growing sales of its flagship product ZORYVE across multiple indications.
For the fourth quarter, Arcutis reported net product revenue of $69.4 million, a staggering 413% increase compared to the prior year quarter. Total revenues came in at $71.4 million, beating analysts' estimates of $60.16 million. On the profitability front, the company reported a loss of $0.09 per share, significantly better than the consensus estimate of a $0.24 loss.
The stellar results were underpinned by the company's robust commercial execution and strong demand for ZORYVE, a topical PDE4 inhibitor approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. ZORYVE is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.